Abstract:Glycogen synthase kinase-3 (GSK3) is one of the important serine/threonine protein kinases and has two isoforms, namely, GSK3α and GSK3β. GSK3 inhibits glycogen synthase activity through phosphorylation. It plays a key role in various pathophysiological processes, such as differentiation, immunity, metabolism, cell death, and cell survival. Therefore, GSK3 has evolved as an important therapeutic target for treating neurological diseases, inflammatory diseases, and cancer. In addition, GSK3 regulates inflammatory processes through NF-κB-induced expression of various cytokines, including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6. Moreover, GSK3 is reported to participate in many signaling pathways related to disease pathology, including PI3K/Akt, Wnt, Hedgehog, cyclic adenosine monophosphate, mitogen-activated protein kinase, and transforming growth factor-β (TGF-β). GSK3 has become a therapeutic target against some inflammatory diseases, including the inclusion body myositis, sepsis, and inflammatory bowel disease. Hence, several GSK3 inhibitors have been under evaluation as new therapeutic strategies in recent years. Two drugs targeting GSK3 have already entered clinical studies, including tideglusib and lithium carbonate. In this study, we analyzed nearly 30 different small-molecule GSK3 inhibitors reported in the past 4 years and classified them into four categories (thiazole, pyridine, F-substituted benzene, and others) according to their structure to conduct further literature research. Moreover, we summarized the optimal compounds and described the process of transformation from the lead compound to the optimal compound. In addition, we aimed to summarize the role of GSK3 in the pathogenesis of inflammatory diseases, with insights into the recent progress in the discovery of GSK3 inhibitors.

Discovery and Anti-Inflammatory Evaluation of Benzothiazepinones (btzs) As Novel Non-Atp Competitive Inhibitors of Glycogen Synthase Kinase-3Β (Gsk-3Β).

Design, Synthesis and Biological Evaluation of Benzothiazepinones (btzs) As Novel Non-Atp Competitive Inhibitors of Glycogen Synthase Kinase-3Β (Gsk-3Β).

Identification of Novel Scaffold of Benzothiazepinones As Non-Atp Competitive Glycogen Synthase Kinase-3Β Inhibitors Through Virtual Screening.

Advances in the Therapeutic Potential of Inhibitors Targeting Glycogen Synthase Kinase 3 in Inflammatory Diseases

ChemInform Abstract: Design, Synthesis and Biological Evaluation of Benzothiazepinones (btzs) As Novel Non‐ATP Competitive Inhibitors of Glycogen Synthase Kinase‐3β (Gsk‐3β).

Design,synthesis and biological evaluation of benzothiazinones as novel non-ATP competitive inhibitors of glycogen synthesis kinase 3β(GSK-3β)

Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3 Inhibitors for the Treatment of Acute Promyelocytic Leukemia

Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors

Scaffold Hopping for Discovery of N, N-dibenzylcinnamamide (DBCA) Derivatives As Novel Allosteric GSK-3β Inhibitors: Design, Synthesis and Anti-Inflammatory Evaluation

Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.

Design, Synthesis, and Evaluation of 3‐aryl‐4‐pyrrolyl‐maleimides As Glycogen Synthase Kinase‐3β Inhibitors

Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.

Design, Synthesis and Evaluation of 7-Azaindazolyl-indolyl-maleimides As Glycogen Synthase Kinase-3Β (Gsk-3Β) Inhibitors

Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3 beta (GSK-3 beta) inhibitors.

Design, synthesis and biological evaluation of thieno[3,2- c ]pyrazol-urea derivatives as potent glycogen synthase kinase 3β inhibitors based on the DFG-out conformation

Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3β (GSK-3β) inhibitors

Synthesis and Biological Evaluation of Novel 4,5-Bisindolyl-1,2,4-triazol-3-ones As Glycogen Synthase Kinase-3Β Inhibitors and Neuroprotective Agents.

Design, Synthesis and in Vitro Test of Novel Non-ATP Competitive Glycogen Synthase Kinase-3β(GSK-3β)Inhibitors

Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia

Design, Synthesis, and Biological Evaluation of Novel 7-Azaindolyl-heteroaryl-maleimides As Potent and Selective Glycogen Synthase Kinase-3 Beta (Gsk-3 Beta) Inhibitors

Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) Inhibitors